Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

502

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

May 24, 2024

Study Completion Date

December 10, 2024

Conditions

Plaque Psoriasis

Interventions

DRUG

BAT2306

150 mg/1 ml/injection (2 injections/visit)

DRUG

EU-approved Cosentyx

150 mg/1 ml/injection (2 injections/visit)

Trial Locations (1)

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou